Overexpression of SEZ6L2 and Immune Infiltration in Cancer Based on Gene Image Diagnosis
View abstract on PubMed
Summary
This summary is machine-generated.The SEZ6L2 gene is linked to poor prognosis and immune invasion in breast cancer. This gene may serve as a new biomarker and therapeutic target for breast cancer (BRCA) patients.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Optical image diagnostic technology advances cancer research.
- The role of the SEZ6L2 gene in cancer immune infiltration is not well understood.
- Investigating SEZ6L2's role can improve cancer diagnosis and treatment.
Purpose Of The Study
- To explore the connection between SEZ6L2 gene overexpression and cancer immune infiltration.
- To utilize optical image diagnostic technology for novel cancer insights.
- To identify potential biomarkers and therapeutic targets in cancer.
Main Methods
- Quantitative assessment of SEZ6L2 gene expression using light image diagnostic technology.
- Immunohistochemical analysis of immune infiltrating cells (TIICs) in tumor tissues.
- Analysis of enrichment pathways including complement activation and immunoglobulin responses.
Main Results
- SEZ6L2 expression correlates with the level of tumor infiltrating immune cells (TIICs).
- Potential links identified between SEZ6L2 expression and TIIC marker genes.
- Enrichment pathways involved complement activation and immunoglobulin-mediated responses.
Conclusions
- Elevated SEZ6L2 mRNA expression in breast invasive carcinoma is associated with poor prognosis and immune invasion.
- SEZ6L2 shows potential as a prognostic biomarker in breast cancer.
- SEZ6L2 may be a viable target for immunotherapy in breast cancer (BRCA).